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Abstract
Background: Several of the intended Plasmodium falciparum vaccine candidate antigens are highly
polymorphic and could render a vaccine ineffective if their antigenic sites were not represented in
the vaccine. In this study, characterization of genetic variability was performed in major B and T-
cell epitopes within vaccine candidate antigens in isolates of P. falciparum from Peru.
Methods: DNA sequencing analysis was completed on 139 isolates of P. falciparum collected from
endemic areas of the Amazon basin in Loreto, Peru from years 1998 to 2006. Genetic diversity was
determined in immunological important regions in circumsporozoite protein (CSP), merozoite
surface protein-1 (MSP-1), apical membrane antigen-1 (AMA-1), liver stage antigen-1 (LSA-1) and
thrombospondin-related anonymous protein (TRAP). Alleles identified by DNA sequencing were
aligned with the vaccine strain 3D7 and DNA polymorphism analysis and FST study-year pairwise
comparisons were done using the DnaSP software. Multilocus analysis (MLA) was performed and
average of expected heterozygosity was calculated for each loci and haplotype over time.
Results: Three different alleles for CSP, seven for MSP-1 Block 2, one for MSP-1 Block 17, three
for AMA-1 and for LSA-1 each and one for TRAP were identified. There were 24 different
haplotypes in 125 infections with complete locus typing for each gene.
Conclusion: Characterization of the genetic diversity in Plasmodium isolates from the Amazon
Region of Peru showed that P. falciparum T and B cell epitopes in these antigens have
polymorphisms more similar to India than to Africa. These findings are helpful in the formulation
of a vaccine considering restricted repertoire populations.
Background
Vaccine design for Plasmodium falciparum is hindered by
polymorphisms in certain vaccine candidate loci [1,2].
Highly polymorphic regions have been observed in P. fal-
ciparum antigenic surface proteins, such as the circumspo-
rozoite protein (CSP), the merozoite surface protein 1
(MSP-1), the apical membrane antigen 1 (AMA-1), the
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liver stage antigen (LSA-1) and the thrombospondin-
related anonymous protein (TRAP) [3].
One of the best characterized and widely accepted by
many as a potential vaccine candidate for P. falciparum is
CSP [4,5]. CSP is a 58-kDa protein and is the major anti-
gen on the surface of malaria sporozoites [6,7]. The CSP
protein can be subdivided into two non-repetitive regions
(N- and C-termini) and a variable central region consist-
ing of several repeats of four-residue long motifs; both
regions exhibit polymorphisms [8-10]. Several T-cell
epitopes have been found in the non-repeat regions while
immunodominant B-cell epitopes have been identified in
the central repeat region [8,11]. RTS, S, AS02, a P. falci-
parum vaccine that consists of the repeat and C-terminal
regions of CSP, has successfully completed Phase IIb trials
in Mozambique [12,13].
Another antigen that is considered as a vaccine candidate
for P. falciparum is MSP-1. MSP-1 is a 195-kDa protein
that is cleaved into an 83-kDa N-terminal fragment, two
central fragments of 30- and 38-kDa and a 42-kDa C-ter-
minal fragment [14,15]. Just before invasion, the 42-kDa
is further cleaved into 33- and 19-kDa fragments (MSP-133
and MSP-119). The MSP-119  protein fragment remains
anchored to the merozoite surface at the time of erythro-
cyte invasion and because of its location is a major target
of naturally-acquired antimalarial immunity [16]. Within
the coding region of the 83-kDa fragment is Block 2,
which is a principal target of antibodies associated with
clinical immunity in African children [17,18]. In contrast
to Block 2, the Block 17 portion of Pfmsp-1, which
encodes the MSP-119 fragment, is conserved with only a
few polymorphic sites that produce non-synonymous
amino acid changes [16,19].
AMA-1 has also been evaluated for inclusion in a multi-
subunit vaccine for both P. falciparum and Plasmodium
vivax. Recombinant AMA-1 induces protective immune
responses in mouse and monkey models of malaria
[20,21] and both monoclonal and polyclonal antibodies
to AMA-1 inhibit merozoite invasion of erythrocytes [22].
As with the other P. falciparum vaccine candidate
sequences, Pfama-1 is highly polymorphic [23-25] with
most of polymorphisms occurring in domain I [22,23,26]
making a broadly effective vaccine difficult to create.
The liver stage-specific antigen, LSA-1 is well conserved
among P. falciparum isolates and is also considered a vac-
cine candidate. Cytokines, such as interferon gamma,
have been implicated in the control of Plasmodium
growth and with protection from reinfections with P. fal-
ciparum [27]. Studies have shown that the N-terminal and
PfLSA-1 protein junction (PfLSA-J) regions of PfLSA-1 pro-
tein, could induce INF-γ by CD8+ T-cells in adults [28].
Yet another candidate for inclusion in a vaccine for P. fal-
ciparum is TRAP [29,30]. As with the many vaccine targets
discussed above, TRAP protein is highly polymorphic.
Studies designed to identify HABPs in TRAP successfully
identified 21 loci, three of which contain B epitopes [31],
while other studies using INF-gamma ELISPOT identified
two CD8+ lymphocyte epitopes [32].
Knowledge of the distribution of polymorphic sites on
malaria antigens is necessary to obtain a detailed under-
standing of their significance for vaccine development.
This is the first report of the variants found in this part of
the Amazon basin; moreover, this study includes infec-
tions occurring early in the Peruvian P. falciparum emer-




Plasmodium falciparum isolates were collected from
endemic areas in the Peruvian Amazon Department of
Loreto during years 1998 to 2006 using human use
approved protocols. Loreto is located in the northeast part
of Peru and encompasses 30% of the Peruvian territory.
The climate is warm and humid, with the rainy season
(December – March) having temperatures reaching 36°C
and the driest season (June – July) having temperatures as
low as 17°C – 20°C.
There were 139 P. falciparum isolates available for this
study, all from P. falciparum-infected individuals living in
or near the city of Iquitos. Twenty-seven of the isolates
were collected in years 1998–1999 from patients diag-
nosed with severe and complicated malaria (courtesy of
Dr. Richard Witzig; IRB NMRCD.2005.0004). Twenty-
four samples were from patients enrolled in a sulphadox-
ine-pyrimethamine  in vivo study conducted in 1999
(WRAIR #719). Thirty-two samples were collected
between years 2003 to 2005 (11 from 2003 and 2005
each and 10 from 2004) from a community in the San
Juan district, approximately five kilometers south of Iqui-
tos, called Zungarococha from individuals participating in
an active malaria detection study, including symptomatic
and asymptomatic individuals (IRB PJT.NMRCD.015; IRB
UAB) [33]. Also, fifty-six samples from year 2006 came
from individuals presenting with malaria-like illness at
clinics located in different communities near Iquitos (IRB
NMRC.2000.0006). All samples obtained were blood
samples confirmed to be positive for P. falciparum by
microscopy.
Reference strain
Strain 3D7, which is the current vaccine strain used by the
US Department of Defense malaria research programmesMalaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
Page 3 of 11
(page number not for citation purposes)
[34], was used for comparative genetic analysis with Peru-
vian sequences.
Genetic analysis of B- and T-cell epitopes
The genetic diversity of 11 DNA regions encoding mainly
T and B cells epitopes in CSP (Pfcsp), MSP-1 (Pfmsp-1
Block 2 and Pfmsp-1 Block 17), AMA-1 (Pfama-1), LSA-1
(Pflsa-1) and TRAP (Pfssp-2) was determined in the iso-
lates. DNA was purified from 200 μL of whole blood
using the QIAamp DNA Blood mini kit. PCR fragments
were generated using primers and conditions listed in
Table 1 in order to amplify DNA regions encoding the
selected T or B cell epitopes. PCR amplification was per-
formed in a 30 μL reaction mixture containing 0.2 μM
each of forward and reverse primers (for Pfmsp-1 0.8 μM
of each primer was used), 200 μM each dNTP, 0.6 units of
DNA polymerase recombinant, 3 μL of 10× PCR buffer,
1.5 mM of MgCl2 and 5 μL of the template extracted from
blood.
The following PCR conditions were used:
Pfcsp genetic variability: 3 min at 94°C, 2 min at 58°C, 2
min at 72°C; 1 min at 94°C, 2 min at 58°C, 1 min at
72°C for 32 cycles and a final extension of 72°C for 10
min; obtaining a PCR product of 318 bp.
Pfmsp-1 genetic variability (Blocks 2 and 17): 5 min at
94°C; 30 sec at 91°C, 40 sec at 50°C, 40 sec at 70°C for
40 cycles and a final extension of 70°C for 5 min; obtain-
ing a PCR product of approximately 400 bp.
Pfama-1 genetic variability: 2 min at 95°C; 1 min at 95°C,
1 min at 55°C, 2 min at 72°C for 30 cycles and a final
extension of 72°C for 2 min; obtaining a PCR product of
803 bp.
Pflsa-1 genetic variability: 5 min at 94°C; 30 sec at 91°C,
40 sec at 45°C, 40 sec at 70°C for 40 cycles and a final
extension of 70°C for 5 min; obtaining a PCR product of
336 bp.
Pfssp-2 genetic variability (Regions II and IV): 5 min at
94°C; 30 sec at 91°C, 40 sec at 50°C, 40 sec at 70°C for
35 cycles; and a final extension of 70°C for 5 min; obtain-
ing PCR products of 1000 bp and 650 bp, respectively.
PCR products were purified using Qiagen PCR spin col-
umns and sequenced using BigDye terminator v3.1 cycle
(Applied Biosystem, Foster City, CA) sequencing kit, the
primers listed in Table 1 and an ABI 3100 automated
sequencer.
Sequence analysis
Sequences were analysed using the Sequencher version
4.7 software (Gene Codes Corporation, Michigan) and
comparative alignments to 3D7 were performed using the
MEGA version 3.1 software [35]. Additionally, strains
7G8, D6 and W2 were sequenced and used as regional ref-
erence strains. Nucleotide diversity, Pi (π) [36,37], which
is the average number of substitutions between any two
sequences, and haplotype (gene) diversity values [36]
were estimated with the DnaSP 4.0 software [38]. The
standard deviation (or standard error) was calculated for
both measures. Statistical Analysis Software (SAS Version
9.3, Cary, NC) was used to test multilocus linkage associ-
ation (MLA) by Fisher Exact Test (FET); two-tailed with
alpha = 0.05. The p-value was multiplied by four to correct
for conducting pairwise comparisons of four antigens. The
antigen diversity was calculated by determining the heter-
ozygosity of alleles detected in each antigen, where heter-
ozygosity (H) = (1 - Sp2), with p2 being the squared
frequency of each allele variant. Wright's F-statistic (Fst) to
evaluate gene flow among the different study years was
determined using DnaSP 4.0 software.
Table 1: List of primers used in this study.
Gene Regions Epitopes Primers 5' – 3' Ref
Pfcsp Th2R Th3R T cell Th2R_3Rf: ACCATCAAGGTAATGGACAAGG
Th2R_3Rr: ACGACATTAAACACACTGGAAC
[8]
Pfmsp-1 block 2 T cell C1_f: AACTAGAAGCTTTAGAAGATGCAG
C3_r: ACATATGATTGGTTAAATCAAAGAG
[16]
Pfmsp-1 block 17 T cell M16_f: CCTAATACAATAATATCAAAATTAATTGA
C3Fla_r: ATTAAGGTAACATATTTTAACTCCTAC
[16]
Pfama-1 Domain I T cell amex5_f: GAACCCGCACCACAAGAAC
amexe_r: TTGTTTAGGTTGATCCGAAGC
[24]
Pflsa-1 N-terminal region T cell lsp_f: AAAATCTAACTTGAGAAGTGGTTCT
lsp_r: TTCTTGTCTGTTTTCGTCTT
Current manuscript
Pfssp-2 Region II T cell B cell ssp-2Af: CGTCGTCATAATTGGGTG
ssp-2Ar: CCTCTTGGTCTAGGTTGAT
Current manuscript
Pfssp-2 Region IV B cell ssp-2Cf: GTTATCGGACCCTTTATG
ssp-2Cr ATAGGGTGTTGCTGCTCC
Current manuscriptMalaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
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Results
Samples were analysed in three major groups, called study-
years: 1998–99, 2003–05 and 2006. Amplified products
from 139 isolates were obtained for Pfcsp; 135 for Pfmsp-
1, 128 for Pfama-1, 137 for Pflsa-1 and 131 for Pfssp-2. In
general, the observed polymorphisms in Peruvian isolates
have been previously reported in other populations from
South America [9,23]. Nonsynonymous substitutions
were found in all regions encoding T and B cell epitopes,
except in Pfssp-2. From all study years, diversity was lowest
in the 1998–99 isolates.
Pfcsp
DNA sequences of the 3' region spanning the Th2R and
Th3R epitopes at the C-terminal portion of CSP were
obtained from the 139 isolates. Results from all samples
showed four different alleles (Table 2), none of them sim-
ilar to the 3D7 strain. In comparison to the 3D7 sequence,
mutation points were observed at residues 329
(Lys→Gln), 332 (Lys→Glu), 333 (Glu→Gln), 336
(Asn→Lys/Gln), 339 (Gln→Lys/Arg), 341 (Ser→Ala), 342
(Leu→Ile), 367 (Asn→Gly), 369 (Pro→Ser),
372(Glu→Gln), 374 (Asp→Asn) and 376 (Ala→Glu), all
located in Th2R and Th3R regions. From the four different
alleles found in Peruvian isolates, allele 1 was the preva-
lent allele in 1998–99 while in 2003–05 and 2006 both
alleles 1 and 2 were commonly found (Table 3). The Peru-
vian Pfcsp sequences were more closely related to 7G8,
HB3 and Ven 765 alleles, which was expected due to the
close geographical origin of the isolates [39]. All polymor-
Table 2: Alleles found in Peruvian isolates.
Gene Allele Amino acid sequences
Pfcsp 326 Th2R 342 367 Th3R 378
3D7 P S D K H I K E Y L N K I Q N S L N K P K D E L D Y A N D
1 . . . . . . E Q . . K . . K . . I . . . . . . . . . E . .
2 . . . . . . E Q . . K . . . . . . G . S . . . . . . E . .
3 . . . . . . E Q . . K . . . . A . . . . . . Q . . . E . .
4 . . . Q . . E K . . Q . . R . . . . . . . . Q . N . E . .
Pfmsp-1 Block 2 Block 17








3 SAQSGASAQSGASAQSGASAQSGTSGPSGPSGT Q K N G f
4 SAQSGTSGTSGPSGTSGPSGTSGPSGTSGPSGTSGPSGT Q K N G f




7 SAQSGTSGTSGTSGTSGTSGPSGPSGT Q K N G f
Pfama-1 259 R1 271 279 R2 287
3D7 G P R Y C N K D E S K R N A K D I S F Q N Y
1 . . . . . . . . . . . . . . . . . . . . . .
2 . . . . . . . . Q . . . . . . . K . . . . .
3 . . . . . . . . . . . . . . . . K . . . . .
Pflsa-1 84 T1 107
3D7 L T M S N V K N V S Q T N F K S L L R 
N L G V S
1.   S . . . . . . . . . . . . . . . . . . . . . .
2.   S . . . . . . . . . . Y . . . . . . . . . . .
3 . . . . . . . . . . . . . . . . . . . . . . . .
Pfssp-2 P1 P2 P3 P4 P5
79 88 201 215 421 435 461 475 504 513
3D7 NLNDNAIHL FLVGHPSDGKCNLY NDKSDRYIPYSPLSP SEDRETRPHGRNNENRS
Y
GLALLACAGLAY
1 ...E.... ............. .............P. .................. ............
Amino acids sequences for major T and B cell epitopes in vaccine candidate antigens from Peruvian isolatMalaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
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phisms were non-synonymous, and most mutations were
at the first or second position of the codons, corroborating
earlier studies [7]. In comparison with 7G8, W2 and HB3
strains, alleles 1 and 2 (Table 2) were exactly the same to
7G8 and HB3 sequences, respectively. It is also interesting
to notice that all the isolates in the present study that
share identical Th2R sequence also share identical Th3R
sequence.
According to DNA polymorphism analysis per study-
years, haplotype diversity values have increased since
1998–99 (0.21882) until 2006 (0.53766); also, the nucle-
otide diversity value for 2006 samples (0.01252) showed
an increment of almost 2.3 times more comparing to the
value obtained for samples from years 1998–99
(0.00539).
Pfmsp-1
The genetic variability in Blocks 2 and 17 of Pfmsp-1 was
determined and compared to the vaccine strain 3D7.
From the 135 samples analysed, 85 samples had the
Pfmsp-1  Block 2 (Pfmsp-1-B2) K1 type and 50 had the
Pfmsp-1-B2 MAD-20 type. Seven different Pfmsp-1-B2 alle-
les were found, five from the K1 type and 2 from the
MAD-20 type (Table 2). Pfmsp-1-B2 allele frequencies dif-
fered by study-year. Considering protein (MSP-1B2) allele
frequencies, study-year 1998–99 only had two MSP1B2
alleles at a frequency of >10%, while study-year 2003–05
had three MSP1B2 alleles at a frequency of >10% (Table
3).
Allele 1 (a K1 type) and Allele 2 (a MAD-20 type) were the
most frequently found in all Peruvian samples. K1 type
alleles commenced with the hexapeptide SAQSGT or
SAQSGA and ended with SGPSGT. Most diversity was due
to duplications or deletions of the repeat motifs SAQ, SGT
and SGP. The MAD-20 type allele started with SGGSVT
and ended with SVASGG and diversity was due to repeti-
tions of SGG and SVA. Synonymous substitutions were
observed for Alanine (GCA/GCT) in K1 isolates and for
Glycine (GGC/GGT) in MAD-20 isolates. Also, Block 2
PCR products of the same size did not necessarily corre-
spond to the same allele family since there were two K1
alleles that were the same base-pair length, but had differ-
ent sequence (Table 3).
Nucleotide sequences for the C-terminal 19-kDa region of
MSP-1 (Block 17) were also determined. Substitutions at
amino acid positions 1644 (Glu→Gln), 1691 (Thr→Lys),
1700 (Ser→Asn), 1701(Arg→Gly) and 1716 (Leu→Phe)
Table 3: Allele frequencies per study-year.
Protein allele Allele All allele All allele p-value 1998–99 2003–05 2006
code description freq count year-study allele freq allele freq allele freq
CSP 1 7G8 0.6739 93 0.8823 0.5625 0.5357
CSP 2 HB3 0.3043 42 0.0784 0.4375 0.4286
CSP 3 Ven765 0.0217 3 0.0196 0 0.0357
CSP 4 peru1 0.0072 1 0.0196 0 0
p-value testing year-study difference; main observation: 0.0001 ; CSP allele 1 decreasing
MSP-1-B2 1 K1-126 0.4962 67 0.4898 0.5625 0.463
MSP-1-B2 2 MAD20-144 0.363 49 0.4082 0.25 0.3889
MSP-1-B2 3 K1-99 0.0593 8 0 0.1563 0.0556
MSP-1-B2 4 K1-117 0.0296 4 0 0 0.0741
MSP-1-B2 5 K1-117 0.037 5 0.0816 0 0.0185
MSP-1-B2 6 MAD20-135 0.0074 1 0 0.0313 0
MSP-1-B2 7 K1-81 0.0074 1 0.0204 0 0
K1 total allele count: 85; MAD20 total allele count: 50
p-value testing year-study difference ; main observation: 0.0167 ; MSP-1-B2 allele 4 increasing
AMA-1 1 3D7 0.8438 108 0.8542 0.8214 0.8462
AMA-1 2 peru1 0.125 16 0.1458 0.1786 0.0769
AMA-1 3 7G8 0.0313 4 0 0 0.0769
p-value testing year-study difference ; main observation: 0.1419; AMA-1 allele 3 increasing
LSA-1 1 SN 0.7391 102 0.5098 0.7742 0.9286
LSA-1 2 TN 0.2464 34 0.4902 0.2258 0.0357
LSA-1 3 SY 0.0145 2 0 0 0.0357
p-value testing year-study difference ; main observation: <0.0001; LSA-1 allele 1 increasingMalaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
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have been previously reported [16,40] but all isolates
from Peru only contained amino acids Gln, Lys, Asn, Gly
and Phe in these positions.
Pfama-1
The alignment of PfAMA-1 domain I included 128 iso-
lates. Regions 259–271 (R1) and 279–287 (R2) are natu-
rally immunogenic T and B cell epitopes and non-
synonymous substitutions were found within these res-
gions in positions 267 (Glu→Gln) and 282 (Ile→Lys)
(Table 2). Overall Pfama-1 Domain I Pervian nucleotide
sequences, 24 variable sites were found, 23 of them corre-
sponding to nonsynonymous substitutions and only one
corresponding to a synonymous substitution. Three dif-
ferent alleles were found in Peru; from which allele 1 had
identical amino acid sequence to the vaccine strain 3D7
with only one nucleotide different (AAA/AAG) in codon
292 (Lys). This was the allele most commonly found, fol-
lowed by allele 2, and then followed by allele 3, which
was only detected in study-year 2006 (Table 3).
Pflsa-1
Sequences of the N-terminal region of Pflsa-1, designated
T1, were aligned from 137 isolates with the 3D7 sequence.
The N-terminal region of LSA-1 has been shown to induce
interferon gamma production in peripheral blood mono-
nuclear cells (PBMC). The alignment showed two non-
synonymous substitutions in aa 85 (Thr→Ser) and aa 96
(Asn→Tyr) and that the most abundant allele for T1 was
allele 1. Alleles 2 and 3 were less frequent (Table 3), the
latter having the same nucleotide sequence as 3D7 (Table
2).
Pfssp-2
The antigenic variability of TRAP, encoded by Pfssp-2, was
assessed at previous discovered CD8+ T-lymphocyte TRAP
epitopes located at amino acids 78–88 (P1) and 504–513
(P5) as well as at B cell epitopes located at amino acids
201–215 (P2), 421–435 (P3) and 461–475 (P4) [31]
(Table 2). The alignment of 131 sequences revealed that
epitopes corresponding to P1, P2, P3, P4 and P5 are
highly conserved in Peruvian isolates. In comparison to
the 3D7 sequence, two substitutions were found at posi-
tions 82 (Asp→Glu) and 434 (Ser→Pro), and all Peruvian
isolates had the same sequence.
Multilocus analysis
For each sample, the combination of alleles detected in
the MSP-1B2, CSP, AMA-1, and LSA-1 (multilocus haplo-
types) were determined. The order, listed above, was
based upon pairwise multilocus association (MLA) analy-
sis demonstrating the most consistent linkage between
MSP-1B2 and the other antigens. The result is a four digit
code where each digit is the allele detected for the respec-
tive loci: twenty-four different multilocus haplotypes were
detected (Table 4). Considering all study-years (1998–99,
2003–05, and 2006 samples all together), MSP-1B2 alle-
les were associated with each of the other loci (p ≤ 0.0001,
Fisher Exact Test [FET]) and CSP alleles were associated
with MSP-1B2 and AMA-1 (p ≤ 0.0001, FET). CSP was also
associated with LSA-1 (p = 0.0003, FET); however, the
linkage was less specific: 47.5% were allele 1 and 1, but
19.0% were allele 1 with 2 and 25.6 were allele 2 with 1.
AMA-1 was only associated with LSA-1, and this was mar-
ginal (p = 0.0401). The only linkage that was observed in
each of the year-study samples was MSP-1B2 with AMA-1
(p < 0.0142, FET), with the allele 1 and allele 1 (and NOT
allele 1 and NOT allele 1) linkage being observed each
year-study. The linkage between CSP and AMA-1 and the
linkage between CSP and MSP-1B2 was observed in the
1998–99 study-year and the 2006 study-year. The MSP-
1B2 and LSA-1 allele linkage (allele 1 with 1 and allele 2
with 2) was only observed in 1998–99. The only MLA
observed in the 2003–05 samples (active case detection)
was between MSP-1B2 and AMA-1 (p = 0.0005, FET), with
MSP-1B2 allele 3 and AMA-1 allele 2, being detected
together 14.3% of the time.
Multilocus nucleotide genetic diversity was determined
and compared for each study-year sampling (1998–99,
2003–05, and 2006). Combining all loci together, the
nucleotide diversity was similar in all study-years (ranging
from 0.2725 to 0.2794); however, the samples collected
in study-year 2003–05 (samples collected in active case
detection) had higher amino acid haplotype diversity
(0.8466 +/-SD 0.033) in comparison to the 1998–99 and
2006 study-years (0.6910 +/- SD 0.055 and 0.7543 +/- SD
0.045, respectively). Likewise, comparing the average
allelic heterozygosity for each antigen, the average across
all antigens was highest in the 2003–05 samples (H =
0.4474) versus 1998–99 (H = 0.4366) and 2006 (H =
0.3975).
The genetic distance, or gene flow, among the 1998–1999,
2003–2005 and 2006 study-years was determined using
Wright's F-statistic, Fst. The Fst for each pairwise compar-
ison was low, ranging from -0.0168 to -0.0050. Therefore,
there was no evidence of genetic isolation by year-study.
The 2003–2005 and 2006 study-years were the most
genetically similar (Fst = -0.0168).
Discussion
Investigating the extent of genetic variation can assist in
the laborious process required in selecting antigens for
further vaccine development. Several P. falciparum and P.
vivax vaccine candidate antigens are highly polymorphic
which could pose a serious problem in the formulation of
vaccines from a single, well-characterized strain. Previous
studies have addressed the diversity and maintenance of
several malarial vaccine candidates in Africa [6]. AnMalaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
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understanding of genetic variability in T and B cell
epitopes of vaccine candidate antigens in P. falciparum
Peruvian isolates from the Amazon basin is presented in
this study.
According to the Pfcsp nucleotide and haplotype diversity
values, Th2R and Th3R regions have higher values than
those obtained for other antigens in this Peru study; nev-
ertheless, Pfcsp nucleotide and haplotype diversity values
in Peru for Th2R and Th3R regions are much lower than
those obtained in Kenya (π  = 0.09772 and 0.07442),
Gambia (π = 0.08789 and 0.06454) and Venezuela (π =
0.08466 and 0.08025). However, Peruvian isolates
exhibit similar Th2R nucleotide diversity values to sam-
ples from Brazil, Vietnam and India [7,9]. Allele 1 has
been previously reported in Iran [41], Brazil [42] and
Gambia [43]; allele 2 in Thailand [44], Iran [41] and
Myanmar (de Stricker et al., unpublished); and allele 3 in
Venezuela [9].
In addition, haplotype diversity for the entire 3' end of
CSP was influenced by both Th2R and Th3R regions exclu-
sively, since all 7 variable sites were contained in these
regions and all of the polymorphims produced nonsyn-
onymous substitutions. Linkage and recombination
events between the Th2R and Th3R regions have been
described in previous studies [9]. In the present study,
haplotype linkage between Pfcsp Th2R and Th3R poly-
morphisms was also observed. Nucleotide and haplotype
diversity values for the entire 3' end of CSP of all samples
were 0.01102 and 0.46387, respectively. These values
show that Peruvian isolates are less diverse than African
and more similar to Indian isolates [9].
CSP is one of the most widely characterized malaria vac-
cine candidate antigens, and the only one whose compo-
nents have gone so far as completion of a successful phase
II b clinical trial [12,45], the generation of relevant
genetic, epidemiologic and immunologic data for the CSP
gene is important, particularly for regions of low malaria
endemicity. It is apparent that diversity in Pfcsp is region-
ally restricted, and that Peru has low genetic polymor-
phism with one predominant allele and variants in a
small number, as in India [10], Vietnam [7] and Thailand
Table 4: Haplotypes defined by allelic variants (1–7) of four antigens MSP-1-B2:CSP:AMA-1:LSA-1 (respectively), comparing the 1998–
99, 2003–05 and 2006 study-years.
Haplotypes
MSP-1:CSP:AMA-1:LSA-1
All 1998–99 2003–05 2006
1111 46 36.2% 19 40.4% 6 21.4% 21 42.0%
1112 5 3.9% 4 8.5% 1 3.6% 0 0.0%
1131 1 0.8% 0 0.0% 0 0.0% 1 2.0%
1211 6 4.7% 0 0.0% 5 17.9% 1 2.0%
1212 2 1.6% 0 0.0% 2 7.1% 0 0.0%
2111 3 2.4% 0 0.0% 1 3.6% 2 4.0%
2112 16 12.6% 14 29.8% 1 3.6% 1 2.0%
2121 1 0.8% 1 2.1% 0 0.0% 0 0.0%
2122 3 2.4% 2 4.3% 1 3.6% 0 0.0%
2211 20 15.7% 0 0.0% 4 14.3% 16 32.0%
2212 2 1.6% 1 2.1% 1 3.6% 0 0.0%
2422 1 0.8% 1 2.1% 0 0.0% 0 0.0%
3121 6 4.7% 0 0.0% 4 14.3% 2 4.0%
3211 1 0.8% 0 0.0% 0 0.0% 1 2.0%
3212 1 0.8% 0 0.0% 1 3.6% 0 0.0%
4212 1 0.8% 0 0.0% 0 0.0% 1 2.0%
4231 3 2.4% 0 0.0% 0 0.0% 3 6.0%
5121 1 0.8% 1 2.1% 0 0.0% 0 0.0%
5212 1 0.8% 1 2.1% 0 0.0% 0 0.0%
5323 1 0.8% 0 0.0% 0 0.0% 1 2.0%
5211 1 0.8% 1 2.1% 0 0.0% 0 0.0%
5221 1 0.8% 1 2.1% 0 0.0% 0 0.0%
6111 1 0.8% 0 0.0% 1 3.6% 0 0.0%
7111 1 0.8% 1 2.1% 0 0.0% 0 0.0%
N = 125 47 28 50
Count of haplotypes = 24 12 12 11
Haplotype diversity (Hd) = 0.7932 0.6910 0.8466 0.7543
Hd standard deviation = 0.028 0.055 0.033 0.045Malaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
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[5]. This suggests that since polymorphisms are restricted
and can be grouped, allelic variants can be included in a
polyvalent vaccine that could be widely effective.
On the other hand, diversity in Pfmsp-1 Block 2 was lower
than reported in P. falciparum isolates studied in other
geographic regions [16]. Neither RO33 nor MR Block 2
alleles were found; although these Block 2 alleles have
been reported in other studies, including Venezuela
[15,46]. The number of alleles detected using this direct
sequencing method is lower than those detected using
PCR-based genotyping methods of samples from other
populations such as Kenya [15] with 20 K1 and 15 MAD-
20 alleles detected by nested PCR from 362 samples.
However, similar results to the Peruvian samples were
found in 104 isolates from Brazil with eight alleles veri-
fied by Southern blot and SSCP-PCR [47]. It is important
to remark that the direct sequencing used in this Peruvian
study only detected one Pfmsp-1  Block 2 per infection
(sample) and, therefore, could underestimate the genetic
diversity by only detecting the more high-density/domi-
nant allele in each infection. Results indicated that 63% of
the isolates in this study where K1 alleles. Although the
3D7 vaccine strain is in the K1 allele family, none of the
Peruvian isolates had the same K1 allele (sequence) as the
vaccine strain 3D7.
Strikingly, nucleotide sequences for the C-terminal 19-
kDa region of MSP-1 (Block 17) showed no diversity at
positions 1644 (Gln), 1691 (Lys), 1700 (Asn), 1701 (Gly)
and 1716 (Phe), while polymorphisms in these positions
have been reported in Brazil, Vietnam and Kenya [48,49].
The 3D7 vaccine strain has the MSP-1 19 kDa haplotype
ETSRL, suggesting that if immunity conferred by monova-
lent vaccines is allele specific, it would have low overall
efficacy in populations where the target allele is in the
minority [50].
Results also showed two non-synonymous substitutions
in R1 and R2 regions of Pfama-1. The extensive number of
non-synonymous polymorphisms outside R1 and R2
described in this study revealed that this gene could
undergo intense selective pressure in these other regions
of AMA-1 upon administration of a full-length peptide
vaccine having a single allele type. The overall genetic
diversity in Pfama-1 domain I (π = 0.00697) is lower than
in the Kenyan and Southeast Asian isolates (π values of
0.01361 and 0.01196, respectively) [23]. From the three
different Pfama-1 alleles found, allele 3 was only present
in samples from 2006 and could have arisen by a new
introduction of this R1-R2 haplotype from another geo-
graphic region or by recombination between alleles 1 and
2 which existed in prior study-years.
Two non-synonymous and no synonymous substitutions
were found in LSA-1 T1 in Peruvian isolates. In compari-
son, within Brazilian, Papua New Guinean and Kenyan
isolates two synonymous substitutions (positions 87 and
104) and three different non-synonymous substitutions
(positions 92, 95 and 104) have been reported [51]. These
data suggest that T cell epitopes of P. falciparum LSA-1 are
highly conserved in field isolates from geographically
diverse regions with varying transmission patterns, since
non much allelic diversity is observed. However, even in
this low and recent transmission region of Peru, we
detected two non-synonymous substitutions.
Pfssp-2 HABPs sequences were highly conserved among
these Peruvian isolates. Part of the peptide 2 sequence has
been reported to be a B cell epitope, recognized by sera
from malaria immune humans living in endemic areas
[52]. Peptides 3 and 4 are located within a region charac-
terized by the presence of a great number of Asn, Lys and
Pro residues. This long stretch of amino acids suggests
configuration binding sites, which could be altered with
just minimal changes in amino acid sequence [31]. For
instance, results showed Pro in site 434 instead of Ser as
in the 3D7 sequence; also, P3 showed a characteristic
sequence in which amino acids Asp and Pro are present
each forth residue and that may allow binding in different
registers [28]. P1 and P5 have been identified as CD8+ T-
lymphocyte epitopes and also showed to be highly con-
served, with just one variation in aa 82 (Glu/Asp) com-
pared to 3D7 strain.
Most of the genetic diversity detected in Peruvian isolates
was attributable to non-synonomous, amino acid
changes. Over time, comparing the allele frequencies in
the 1998–1999, 2003–2005 and 2006 study-years, there
were changes in allele frequencies with new alleles being
detected. The 2006 samples had the highest allele counts.
Although multilocus associations were detected, these
associations were most evident in the year 1998–1999
samples. Interestingly, the 2003–2005 study-year samples
had the least multilocus associations (only MSP-1B2 and
AMA-1 polymorphisms were determined to be associ-
ated) and had the greatest overall allelic diversity (H =
0.8466). The diversification observed over time might be
attributed to natural selection from a specific immune
response. In particularly, regarding the 2003–2005 sam-
ples, these samples were collected in active case detection
in a population where the frequency of asymptomatic
infections suggests immune pressure [37].
Several studies have demonstrated the importance of T
and B cell mediated immunity to malaria and how non-
synonymous substitutions may affect the conformation of
epitopes and in consequence the immunological response
[53]. Nevertheless, more studies need to be done in orderMalaria Journal 2008, 7:93 http://www.malariajournal.com/content/7/1/93
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to understand the immunological implications of amino
acid changes in these malaria vaccine candidate antigens.
Studying different genes and their alleles help us to under-
stand if they interact to influence in malaria infection and
if minimal changes in their sequence could render a vac-
cine ineffective. An alternative to improve the effective-
ness of a vaccine would be to create a construct using the
most common regional specific alleles considering the
genetic diversity found in the area. By providing informa-
tion about the prevalence and dynamics of vaccine candi-
date antigens polymorphisms, an accurate construct could
be built.
Conclusion
Peruvian isolates are less polymorphic than African and
more like Indian populations. Although, conserved
epitopes were found in Peru, the observation of uneven
geographic distribution of polymorphisms and the high
number of alleles distributed worldwide, especially for
CSP and MSP-1 Block 2 may have an adverse impact on
the effectiveness of vaccines. The number of allelic vari-
ants increased over time in this study, suggesting that even
in geographic regions with low transmission, vaccine
strategy development should include conduction of diver-
sity studies. The uneven geographic distribution of alleles
may jeopardize the formulation and use of vaccines
directed on a specific variable loci since local variants may
not be considered in the vaccine design.
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